Back to Network
4
Shared Docs
4
Same-Page
4 / 4
Mentions
Document Mentions (4 shared documents)
2 mentions1 same-page
Page ?Same page
The Final Frontier? Inhibitor Cocktails to Stamp out Cancer The use of mutation-specific. inhibitor drugs to fight cancer has been growing in popularity around the wor
f Ile. Bert Vogelstein, the lYinzetor of the Ludwig Center for Cancer Genetics and 'Therapeutics at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine. Dr. Vogelstein was studying resistance to a colon cancer inhibitor called panitumumab. Enlisting Dr. Nenvak's help. Vogelstein and the PED designed
2 mentions1 same-page
Page ?Same page
The Final Frontier? Inhibitor Cocktails to Stamp out Cancer The use of mutation-specific. inhibitor drugs to fight cancer has been growing in popularity around the wor
f Ile. Bert Vogelstein, the lYinzetor of the Ludwig Center for Cancer Genetics and 'Therapeutics at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine. Dr. Vogelstein was studying resistance to a colon cancer inhibitor called panitumumab. Enlisting Dr. Nenvak's help. Vogelstein and the PED designed
2 mentions1 same-page
Page ?Same page
The Final Frontier? Inhibitor Cocktails to Stamp out Cancer The use of mutation-specific, inhibitor drugs to fight cancer has been growing in popularity around the wor
n of Dr. Bert Vogelstein, the Director of the Ludwig Center for Cancer Genetics and Therapeutics at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine. Dr. Vogelstein was studying resistance to a colon cancer inhibitor called panitumumab. Enlisting Dr. Nowak's help, EFTA00583237 Vogelstein and t
Sponsored
2 mentions1 same-page
Page ?Same page
The Final Frontier? Inhibitor Cocktails to Stamp out Cancer The use of mutation-specific. inhibitor drugs to fight cancer has been growing in popularity around the wor
on of Dr. Ben Vogelstein. the Director of the Ludwig Ccntcr for Cancer Genetics and Therapeutics at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine. Dr. Vogelstein was studying resistance to a colon cancer inhibitor called panitumumab. Enlisting Dr. Nowak's help. Vogelstein and the PED designed
Sponsored
Mutual Connections (16)
Entities connected to both The Final Frontier and Johns Hopkins University School of Medicine
Jeffrey Epstein
PERSON4 w/ The·5 w/ Johns
Martin Nowak
PERSON4 w/ The·4 w/ Johns
the Program for Evolutionary Dynamics
ORGANIZATION4 w/ The·4 w/ Johns
VO
Vogelstein
PERSON4 w/ The·4 w/ Johns
the National Institute of Cancer
ORGANIZATION4 w/ The·4 w/ Johns
Massachusetts General
ORGANIZATION3 w/ The·3 w/ Johns
BV
Bert Vogelstein
PERSON3 w/ The·3 w/ Johns
Johns Hopkins
ORGANIZATION2 w/ The·3 w/ Johns
the Journal of Oncology
ORGANIZATION2 w/ The·2 w/ Johns
Journal of Oncology
ORGANIZATION2 w/ The·2 w/ Johns
a Biology and Mathematics
ORGANIZATION2 w/ The·2 w/ Johns
Johns I Iopkins
ORGANIZATION2 w/ The·2 w/ Johns
trials pandit&
ORGANIZATION2 w/ The·2 w/ Johns
ET
EGER TX
PERSON2 w/ The·2 w/ Johns
TG
the lYinzetor of the Ludwig Center for Cancer Genetics
PERSON2 w/ The·2 w/ Johns
NE
Nenvak
PERSON2 w/ The·2 w/ Johns